How to Get Oral Micronized Progesterone in Pennsylvania

Pennsylvania Telehealth Laws and Progesterone Prescribing

Pennsylvania permits telehealth prescribing for hormone therapy, including oral micronized progesterone. Under Act 150 of 2020, the state expanded telehealth access so that licensed prescribers can evaluate patients, order labs, and write prescriptions via synchronous audio-video visits. No in-person visit is required before the initial prescription.

This matters for progesterone access because many Pennsylvania counties, particularly rural ones in the northern and central regions, have limited endocrinology and menopause-specialist coverage. The American College of Obstetricians and Gynecologists (ACOG) endorsed telehealth for routine gynecologic care, including HRT management, in its 2020 committee opinion. Telehealth platforms operating in Pennsylvania must employ providers who hold an active Pennsylvania medical license or a license recognized under interstate compacts.

A prescriber will typically confirm menopausal status through labs and symptom history before writing a progesterone prescription. The Endocrine Society's 2015 clinical practice guideline recommends adding a progestogen for any woman with an intact uterus who receives systemic estrogen therapy, to prevent endometrial hyperplasia [1]. Oral micronized progesterone is the preferred progestogen in that guideline because of its neutral-to-favorable cardiovascular profile compared to synthetic progestins.

Who Can Prescribe: MD, NP, and PA Scope in Pennsylvania

Three categories of licensed providers can prescribe oral micronized progesterone in the state. MDs and DOs have independent prescribing authority. Certified Registered Nurse Practitioners (CRNPs) in Pennsylvania gained full practice authority in 2022 for Schedule II through V controlled substances, and since progesterone is not a controlled substance, CRNPs can prescribe it without a collaborative agreement. Physician Assistants still require a written collaborative agreement with a supervising physician under Pennsylvania's Medical Practice Act.

For telehealth-based HRT, the prescribing provider must document a clinical evaluation that includes menstrual history, vasomotor symptom severity, and contraindications to progesterone therapy. The FDA-approved labeling for Prometrium lists active thrombophlebitis, known or suspected breast cancer, undiagnosed vaginal bleeding, and hepatic dysfunction as contraindications [2]. Prescribers conducting telehealth visits are held to the same documentation standard as in-person encounters.

Required Labs Before Starting Therapy

Before prescribing oral micronized progesterone for endometrial protection, most clinicians order a focused lab panel. This is not optional. The North American Menopause Society (NAMS) 2022 position statement specifies that baseline evaluation should include serum FSH to confirm menopausal status when clinical history is ambiguous, along with estradiol to guide estrogen dosing [3].

A standard pre-HRT panel in Pennsylvania practice includes:

• Serum FSH and estradiol to confirm menopause (FSH >30 mIU/mL, estradiol <30 pg/mL in postmenopausal women)
• Lipid panel because the PEPI trial (JAMA, 1995; N=875) demonstrated that micronized progesterone preserved estrogen's favorable effect on HDL cholesterol, while medroxyprogesterone acetate partially reversed it [4]
• Hepatic function tests (ALT, AST) since oral progesterone undergoes first-pass hepatic metabolism and is contraindicated in patients with hepatic impairment per the FDA label [2]
• Endometrial thickness via transvaginal ultrasound if the patient reports any postmenopausal bleeding, per ACOG Practice Bulletin No. 128 [5]
• Serum progesterone at baseline if there is suspicion of residual ovarian function

Telehealth providers can order these labs through national draw networks (Quest, Labcorp) with locations across Pennsylvania, including Philadelphia, Pittsburgh, Allentown, and Erie. Results are typically available within 48 to 72 hours.

Dosing: Cyclic vs. Continuous Regimens

The FDA-approved dosing of Prometrium for endometrial protection is 200 mg orally at bedtime for 12 consecutive days per 28-day cycle when used with conjugated estrogens [2]. This cyclic regimen produces a scheduled withdrawal bleed in most women.

An alternative is the continuous regimen: 100 mg nightly without interruption. The continuous approach avoids cyclical bleeding, which many patients prefer. A randomized trial published in Obstetrics & Gynecology (Archer et al., 2001) found that continuous 100 mg micronized progesterone combined with 1 mg estradiol reduced endometrial hyperplasia incidence to 0% over 12 months, comparable to cyclic dosing [6]. Breakthrough spotting is more common during the first 3 to 6 months of continuous therapy.

Bedtime dosing is standard because oral micronized progesterone produces active metabolites, including allopregnanolone, that cause drowsiness. The REPLENISH trial (Obstet Gynecol, 2018) confirmed that TX-001HR, a combination of estradiol and micronized progesterone, was effective for vasomotor symptoms and endometrial safety, with somnolence reported in approximately 4% to 6% of participants at the 100 mg progesterone dose [7].

Pharmacy Options in Pennsylvania

Pennsylvania residents can fill oral micronized progesterone prescriptions at retail chain pharmacies (CVS, Walgreens, Rite Aid, Weis), independent pharmacies, and licensed 503A compounding pharmacies. Generic micronized progesterone capsules (100 mg and 200 mg) are widely stocked. Brand-name Prometrium may require special ordering at smaller pharmacies.

For patients seeking customized dosing (for example, 50 mg or 150 mg capsules not commercially available), Pennsylvania-licensed 503A compounding pharmacies can prepare oral micronized progesterone capsules. The Pennsylvania State Board of Pharmacy requires 503A pharmacies to compound pursuant to a valid patient-specific prescription and in compliance with USP <795> standards. These pharmacies may ship within the state.

Pricing varies. Without insurance, generic oral micronized progesterone typically costs $15 to $45 for a 30-day supply at Pennsylvania retail pharmacies. GoodRx and manufacturer discount cards can reduce out-of-pocket cost further. The FDA Orange Book lists multiple AB-rated generic equivalents to Prometrium, confirming therapeutic equivalence [8].

Insurance Coverage and Pennsylvania Medicaid

Pennsylvania Medicaid covers oral micronized progesterone for its FDA-approved indication (endometrial protection during estrogen-based HRT). Prior authorization is required. The Pennsylvania Department of Human Services preferred drug list classifies generic micronized progesterone as a covered product, though formulary placement and tier status can shift with annual updates.

Private insurers in Pennsylvania, including Highmark, UPMC Health Plan, Geisinger Health Plan, and Independence Blue Cross, generally cover generic micronized progesterone on Tier 1 or Tier 2 formularies. Brand Prometrium is typically placed on a higher tier or requires step therapy through the generic first.

For prior authorization, the insurer typically requires:

• Documented menopausal status
• Concurrent estrogen prescription
• Presence of an intact uterus
• Lab results confirming indication

Prior authorization decisions are usually returned within 24 to 72 hours. Pennsylvania insurance regulations under Act 68 require insurers to provide an expedited review within 24 hours for urgent requests.

The Women's Health Initiative (WHI) findings in 2002 led many insurers to tighten HRT prior authorization requirements [9]. Prescribers should note in the authorization request that oral micronized progesterone was not the progestogen studied in WHI (that trial used medroxyprogesterone acetate), and that subsequent data, including the E3N French cohort study (Breast Cancer Res Treat, 2008; N=80,377), showed micronized progesterone was associated with no significant increase in breast cancer risk over a mean follow-up of 8.1 years, unlike synthetic progestins [10].

Transferring a Prescription to Pennsylvania

Patients relocating to Pennsylvania or traveling from another state can transfer an existing oral micronized progesterone prescription. Pennsylvania Board of Pharmacy regulations permit prescription transfers between licensed pharmacies. The receiving pharmacy contacts the originating pharmacy to verify the prescription, remaining refills, and prescriber information.

For telehealth patients, some platforms handle the transfer process directly by issuing a new Pennsylvania prescription based on the existing medical record. Because progesterone is not a controlled substance, the DEA transfer restrictions that apply to Schedule II drugs do not apply here. A standard transfer takes 1 to 3 business days.

If the original prescription was written by an out-of-state provider, that provider must either hold a Pennsylvania license or the patient must establish care with a Pennsylvania-licensed prescriber. The Interstate Medical Licensure Compact, which Pennsylvania joined, simplifies this process for physicians holding compact licenses.

Timeline: From Consultation to Medication in Hand

The typical timeline for a new patient in Pennsylvania:

1. Telehealth consultation: scheduled within 1 to 5 days of request
2. Lab draw: completed within 1 to 3 days at a local draw site
3. Lab review and prescription: 1 to 2 days after results are available
4. Pharmacy fulfillment: same day for retail pickup; 3 to 7 business days for mail-order

Total elapsed time from initial request to medication in hand ranges from 5 to 14 days for most Pennsylvania patients. Patients in Philadelphia and Pittsburgh metro areas tend toward the shorter end due to greater lab and pharmacy density.

Safety Monitoring on Therapy

Once a patient begins oral micronized progesterone, follow-up monitoring is straightforward but clinically necessary. The Endocrine Society guideline recommends reassessment at 3 months after initiation, then annually [1]. Each follow-up should include symptom review, blood pressure measurement, and evaluation of any abnormal bleeding.

Annual mammography is recommended per the U.S. Preventive Services Task Force (USPSTF) breast cancer screening guidelines for women aged 50 to 74 [11]. Endometrial biopsy is not routinely required on micronized progesterone but should be performed if unscheduled bleeding persists beyond 6 months of therapy, per ACOG guidelines [12].

The KEEPS trial (Ann Intern Med, 2014) followed 727 recently postmenopausal women for 4 years and found that oral conjugated equine estrogen plus cyclic micronized progesterone did not significantly increase carotid intima-media thickness or coronary calcium scores compared to placebo [13]. This trial reinforced the cardiovascular safety of micronized progesterone within the early postmenopausal window.

Liver function testing should be repeated at the 3-month visit and annually thereafter. If ALT exceeds 3 times the upper limit of normal, therapy should be discontinued and the patient referred for hepatology evaluation per the Prometrium prescribing information [2].

Peanut Allergy and Prometrium: A Pennsylvania-Specific Note

Brand-name Prometrium capsules contain peanut oil. Patients with confirmed peanut allergy should receive a generic formulation that does not contain peanut oil, or a compounded preparation. The FDA Safety Communication notes this allergen risk on the product label [14]. Pennsylvania 503A compounding pharmacies can prepare peanut-oil-free micronized progesterone capsules using alternative suspension vehicles such as olive oil or sunflower oil.

Prescribers should document peanut allergy status before writing a Prometrium-specific prescription. Several generic manufacturers have already removed peanut oil from their formulations. Confirm the inactive ingredient list with the dispensing pharmacy at the time of fill.